

LIS010433825B2

(12) United States Patent

DeAnglis et al.

(54) DEVICE AND METHOD FOR PREPARING AND ADMINISTERING ONE-COMPONENT FIBRIN SEALANT

(71) Applicants: Ethicon, Inc., Somerville, NJ (US); Omrix Biopharmaceuticals Ltd., Rehovot (IL)

(72) Inventors: Ashley DeAnglis, Skillman, NJ (US);
Yair Pilpel, Rehovot (IL); Yuri
Zherdev, Rehovot (IL); Sivan Doron,
Moshav Arugot (IL); Lior Erez,

Rehovot (IL)

(73) Assignees: Ethicon, Inc., Somerville, NJ (US);

Omrix Biopharmaceuticals Ltd.,

Rehovot (IL)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35

U.S.C. 154(b) by 0 days.

(21) Appl. No.: 14/668,341

(22) Filed: Mar. 25, 2015

(65) Prior Publication Data

US 2015/0272562 A1 Oct. 1, 2015

Related U.S. Application Data

(60) Provisional application No. 61/970,929, filed on Mar. 27, 2014.

(30) Foreign Application Priority Data

(51) **Int. Cl.**A61M 5/178 (2006.01)

A61L 15/32 (2006.01)

(Continued)

(52) **U.S. Cl.**CPC *A61B 17/00491* (2013.01); *A61K 38/36* (2013.01); *A61K 38/363* (2013.01); (Continued)

(10) Patent No.: US 10,433,825 B2

(45) **Date of Patent:**

Oct. 8, 2019

(58) Field of Classification Search

(56) References Cited

U.S. PATENT DOCUMENTS

4,627,879 A 12/1986 Rose et al. 4,874,368 A 10/1989 Miller et al. (Continued)

FOREIGN PATENT DOCUMENTS

EP 0037393 10/1981 EP 0839498 5/1998 (Continued)

OTHER PUBLICATIONS

Bio-Rad Protein Purification Bio-ScaleTM Mini Cartridges, Jul. 2006: 2 pages total.*

(Continued)

Primary Examiner — Marsha Tsay (74) Attorney, Agent, or Firm — David R. Crichton

(57) ABSTRACT

Provided herein are systems for preparing and delivering fibrin sealant to a surface and methods of use thereof. In one embodiment, the system comprises: a. a quantity of a liquid mixture disposed within a container, the mixture comprising: I. fibrin or II. fibrinogen and Factor II; and b. a resin bed disposed within a vessel, the vessel capable of being in fluid communication with the container, wherein when in fluid communication, passage of the mixture through the vessel results in modification of the concentration of small molecules inhibitor(s) and/or inducer(s) within the mixture, favoring fibrin clot formation.

24 Claims, 8 Drawing Sheets Specification includes a Sequence Listing.



